登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H18FN3O3
化学文摘社编号:
分子量:
319.33
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
诺氟沙星, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
SMILES string
CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3
InChI key
OGJPXUAPXNRGGI-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
norfloxacin
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
诺氟沙星通过干扰 ATP 诱导转换 DNA 与 DNA 旋转酶（拓扑异构酶）复合物的结构转换而阻断 DNA 复制。
操作方式：抑制细菌 DNA 复制
抗菌谱：革兰氏阴性菌； 对革兰氏阳性菌效果较差
操作方式：抑制细菌 DNA 复制
抗菌谱：革兰氏阴性菌； 对革兰氏阳性菌效果较差
Application
Norfloxacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.
D R Nalin
European journal of cancer & clinical oncology, 24 Suppl 1, S55-S61 (1988-01-01)
E J Goldstein
The American journal of medicine, 82(6B), 3-17 (1987-06-26)
Norfloxacin is an orally absorbed fluoroquinolone antibacterial with a fluorine at position 6 and a piperazine ring at position 7. These changes have resulted in a marked enhancement (compared with that of the older quinolones) of in vitro antibacterial activity.
L Miano et al.
European urology, 17 Suppl 1, 13-18 (1990-01-01)
A review of worldwide clinical trials with norfloxacin in the treatment of uncomplicated urinary tract infections (UTIs), as well as our personal experience with 215 assessable patients, is presented. Almost all patients received 400 mg b.i.d. for 3-15 days. Bacteriological
Ying-Jun Zhou et al.
FEMS microbiology letters, 355(2), 124-130 (2014-05-13)
The antimicrobial activity of one 3-hydroxypyridin-4-one (HPO) hexadentate (1) and three HPO hexadentate-based dendrimeric chelators (2-4) was evaluated. They were found to exhibit marked inhibitory effect on the growth of two Gram-positive bacteria and two Gram-negative bacteria. The combination treatment
J S Wolfson et al.
Annals of internal medicine, 108(2), 238-251 (1988-02-01)
Norfloxacin is an oral fluoroquinolone antimicrobial agent recently released for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication. Norfloxacin is more potent and broader in spectrum than
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持